Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
May 20, 2024

ERS Genomics and IRBM sign deal for CRISPR technology

ERS Genomics and IRBM have entered into a non-exclusive license agreement, granting the latter access to ERS Genomics' extensive clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 patent portfolio.

The editing technology will also be integrated into comprehensive drug discovery services of IRBM. Credit: Tung Lam from Pixabay.